{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005463","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.568687+00:00","generated_at":"2026-05-17T12:15:17.026617+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptose reports tuspetinib triplet achieves 90% CR/CRh in newly diagnosed AML Phase 1/2 trial","bullets":["100% CR/CRh at 80 mg and 120 mg TUS doses in combination with VEN+AZA (9/10 subjects).","78% MRD-negativity among responders (7/9); 100% MRD-negativity in TP53, RAS, FLT3-ITD subgroups.","No dose-limiting toxicities or prolonged myelosuppression; enrollment advancing to 160 mg cohort.","Single non-responder was at 40 mg dose with subtherapeutic TUS exposure; all other patients remain on study."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005463","json":"https://secwatch.observer/filing/0001171843-25-005463.json","markdown":"https://secwatch.observer/filing/0001171843-25-005463.md","text":"https://secwatch.observer/filing/0001171843-25-005463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005463/0001171843-25-005463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005463/f8k_081825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:15:17.026617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}